Skip to main content

Table 1 Total Medication Cost of Patients with MS in 2019–20

From: Estimation the medical cost of multiple sclerosis in Iran; 2019–2020

Drug Generic Name

Number of Patients received MS medications (IHIO)

Total Drug Cost (1000 $)

Copayment Share (%)

Out of Pocket (1000 $)

IHI Cost share (1000 $)

Cost Per Patient ($)

OOP per Patients ($)

Estimate of Country Total Cost (1000 $)

Share in the Total Cost (%)

Beta-Interferon

21,019

56,280.1

13

7316.4

48,963.7

2677.5

348.08

112,560.3

58.53

Glatiramer Acetate

1434

4251.1

10

425.1

3826.06

2964.5

296.4

8502.3

4.42

Dimethyl Fumarate

8779

7546.4

30

2263.9

5282.5

859.6

257.8

15,092.9

7.84

Fingolimod

7333

7585.4

5

379.2

7206.1

1034.4

51.7

15,170.8

7.88

Teriflunomide

1553

1540.8

30

462.2

1078.5

992.1

297.6

3081.6

1.60

Rituximab

9506

13,470.7

10

1347.07

12,123.7

1417.08

141.7

26,941.5

14.01

Natalizumab

724

5459.05

10

545.9

4913.1

7540.1

754.01

10,918.1

5.67

Cyclophosphamide

192

6.37

10

0.63

5.73

33.1

3.3

12.7

0.006

Mitoxantrone

102

8.88

10

0.88

8

87.1

8.7

17.7

0.009

Total

50,642

96,149.19

13.25

12,741.51

83,407.68

17,605.87

2159.54

192,298.38

100